Ascletis Pharma Inc. (HKG:1672)
Hong Kong · Delayed Price · Currency is HKD 8.37
+0.07 (0.78%)
Sep 30, 2026, 4:08 PM HKT
Ascletis Pharma Market Cap
Ascletis Pharma has a market cap or net worth of 8.77 billion as of September 29, 2026. Its market cap has decreased by -8.80% in one year.
Market Cap
8.77B
Enterprise Value
6.15B
Revenue
1.09M
Ranking
n/a
PE Ratio
n/a
Stock Price
8.37
ChartMarket Cap Chart
Since August 1, 2018, Ascletis Pharma's market cap has decreased from 15.69B to 8.77B, a decrease of -44.12%. That is a compound annual growth rate of -6.88%.
| Date | Market Cap | % Change |
|---|---|---|
| Sep 30, 2026 | 8.77B | -22.00% |
| Dec 31, 2025 | 11.24B | 287.10% |
| Dec 31, 2024 | 2.90B | 90.74% |
| Dec 29, 2023 | 1.52B | -70.46% |
| Dec 30, 2022 | 5.15B | 44.13% |
| Dec 31, 2021 | 3.58B | 13.38% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro |
| Aug 1, 2018 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| HBM Holdings | 11.38B |
| GenFleet Therapeutics (Shanghai) | 11.07B |
| Ascentage Pharma Group International | 10.63B |
| Nanjing Leads Biolabs | 10.20B |
| Everest Medicines | 9.74B |
| Suzhou Ribo Life Science | 8.92B |
| CStone Pharmaceuticals | 8.50B |
| LongBio Pharma (Suzhou) | 8.42B |